Radiotherapy vs Catheter Ablation for Ventricular Tachycardia in Structural Heart Disease
The goal of this randomized clinical trial is to test the efficacy of stereotactic body radiation therapy (SBRT) in treating ventricular tachycardia (VT) in patients with advanced structural heart disease. The main questions it aims to answer are: * What is the efficacy of SBRT compared to catheter ablation (CA) in achieving a ≥ 75% reduction in VT burden at 6 months * What is the comparable safety profile of SBRT vs CA Researchers will compare SBRT and CA (standard of care).
• Structural heart disease (including ischaemic cardiomyopathy , non-ischaemic cardiomyopathy or congenital heart disease and defined as any one of
‣ segmental or global decreased ventricular wall motion as defined by TTE, CT or cMRI
⁃ myocardial hypertrophy
⁃ myocardial scar (evidenced by late gadolinium enhancement on cMRI, wall thinning on cardiac CT, low voltage on electrophysiological study or abnormal intracardiac echocardiography)
• Recurrent monomorphic VT which can include
‣ at least one episode of VT treated by ICD and/or
⁃ sustained VT (lasting \>30s) and/or
⁃ inducible sustained VT on invasive electrophysiological study (EPS) or non-invasive programmed stimulation (NIPS)
• PAINESD score of ≥9 points and/or at least moderate risk of VT recurrence or death as defined by the I-VT score. Both are validated tools used clinically to identify patient at high risk of VT recurrence and/or mortality after CA.